Precede Biosciences Presents Data at AACR 2025 Demonstrating Ability to Resolve Gene Expression for Thousands of Tumor-Specific Genes from a Simple Blood TestBOSTON, April 27, 2025 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared the company’s scientific presentation from the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25 to 30, 2025, in Chicago, Illinois.
Precede Biosciences Presents a Novel ER Transcriptional Dependency Index at SABCS 2024 Designed to Further Inform Use of Endocrine Therapy from a Simple Blood TestBOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared the company’s scientific presentation from the 2024 San Antonio Breast Cancer Symposium (SABCS) taking place from December 10 to 13, 2024 in San Antonio, Texas.
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood TestBOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared the company’s scientific presentations from the 2024 American Association for Cancer Research (AACR) Special Conference In Cancer Research: Liquid Biopsy (AACR LBx 2024) taking place from November 13 to 16, 2024 in San Diego, California.
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024BOSTON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared the company’s scientific poster presentation from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Annual Meeting taking place from September 18 to 20, 2024 in Copenhagen, Denmark.
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET ImagingBOSTON, Sept. 15, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared the company’s scientific poster presentation from the 2024 European Society for Medical Oncology (ESMO) Annual Meeting taking place from September 13 to 17, 2024 in Barcelona, Spain.
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood TestBOSTON, June 02, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared two scientific poster presentations from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4, 2024 at McCormick Place in Chicago, Illinois.
Data Presented at AACR 2024 Showcase Precede Biosciences’ Power to Impact Precision Medicine from a Simple Blood TestBOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared three scientific poster presentations from the 2024 American Association for Cancer Research (AACR) Annual Meeting.
Precede Biosciences to Present Scientific Data For Its Comprehensive Epigenomic Liquid Biopsy Platform at AACR 2024New data in gastro-esophageal and lung cancers show the transformative potential of the platform in providing resolution into the activation status of clinically actionable genes and pathways from a simple blood draw
Data Presented at SABCS Demonstrate the Significant Promise of Precede Biosciences’ Novel Liquid Biopsy Platform to Define HER2 and ER Status in Patients With Advanced Breast CancerBOSTON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, today announced that data from its platform were presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX. The data demonstrate the ability of the platform to reveal disease-defining transcriptional biology of metastatic breast cancer and to accurately classify patients as HER2 3+ vs. HER2 0 and ER+ vs. ER- from just 1mL of plasma.
Data Demonstrating Precede Biosciences' Ability to Determine HER2 Status from 1mL of Plasma to be Presented at the 2023 San Antonio Breast Cancer SymposiumBOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, announces that data supporting the use of its platform to determine HER2 status in patients with metastatic breast cancer will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). The meeting will be held December 5-9 in San Antonio, TX.
Precede Biosciences Announces First Scientific Data from its Liquid Biopsy Platform to be Presented as an Oral Presentation at ESMO 2023Data from more than 400 patients across 15 cancers demonstrate the significance of the Precede approach to informing therapeutic decision making and clinical diagnoses
Precede Biosciences Emerges from Stealth to Dramatically Impact Precision Medicine with a First-in-Class Liquid Biopsy PlatformUnique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activation of individual genes and pathways in diseased tissues from just 1mL of plasma
